Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data from a Phase II clinical trial demonstrating that its ultra rapid acting intranasal insulin was both superior to usual therapy (oral anti-diabetic medicines and/or basal insulin) and non-inferior to insulin aspart (NovoLog�), a rapid-acting injectable insulin, in maintaining glucose control at both 60 and 90 minutes following a meal. The data also demonstrated a statistically significant reduction in the incidence of hypoglycemia (low blood sugar
Grafico Azioni Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Nastech Pharmaceutical Company (MM)
Grafico Azioni Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Nastech Pharmaceutical Company (MM)